Reaction
Follicular Lymphoma Recurrent reporting signals
As of the last recalculation, Follicular Lymphoma Recurrent appears in 71 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is OBINUTUZUMAB (PRR 979.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Obinutuzumab | 31 | 979.8 | 981.6 |
| Polatuzumab Vedotin | 11 | 390.8 | 391.3 |
| Vincristine Sulfate | 25 | 385.5 | 385.8 |
| Bendamustine Hydrochloride | 9 | 252.1 | 252.3 |
| Bendamustine Hcl | 11 | 245.9 | 246.1 |
| Doxorubicin Hydrochloride | 18 | 216.1 | 216.2 |